- To complete this test successfully, answer all questions obtaining 10/10.
- You can repeat the test all the times you need but remember to answer all questions.
- You will require 30 minutes approximately to complete all the questions.
Test Summary
0 of 10 questions completed
Questions:
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
Information
You have already completed the test before. Hence you can not start it again.
Test is loading…
You must sign in or sign up to start the test.
You must first complete the following:
Results
Results
0 of 10 questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- Answered
- Review
-
Question 1 of 10
1. Question
In HER2 positive breast cancer, what is the standard first-line treatment for metastatic disease?
CorrectIncorrect -
Question 2 of 10
2. Question
In HER2 positive breast cancer, what is the standard second-line treatment for metastatic disease?
CorrectIncorrect -
Question 3 of 10
3. Question
In HER2-positive breast cancer, what is the standard third-line treatment for metastatic disease?
CorrectIncorrect -
Question 4 of 10
4. Question
The mechanism of action of margetuximab is as follows:
CorrectIncorrect -
Question 5 of 10
5. Question
In the NALA study, the combination of Neratinib + capecitabine demonstrated.
CorrectIncorrect -
Question 6 of 10
6. Question
The most common toxicity of neratinib + capecitabine is:
CorrectIncorrect -
Question 7 of 10
7. Question
Progression-free survival with DS 8201 for patients with metastatic breast cancer in the DESTINY-Breast01 study was:
CorrectIncorrect -
Question 8 of 10
8. Question
The potentially most serious toxicity of DS8201 is:
CorrectIncorrect -
Question 9 of 10
9. Question
In the HER2CLIMB study, indicate which statement is false:
CorrectIncorrect -
Question 10 of 10
10. Question
The most common toxicity of tucatinib + capecitabine + trastuzumab is:
CorrectIncorrect